Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 56.68

-2.4%

Dec 12 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (14052)	11/18/2004 10:12:54 PM
From: Archie Meeties	Read Replies (2) of 52153

Peter, I've been going through your list (a helpful orientation) from smallest market cap to largest, and I'm stuck on CTIC. Oncology is a weak spot for me. In any case, I was reviewing your CTIC posts and I came across this regarding the p3 trial of ct-2103 "you could have recurrent disease that was previously treated and be eligible even though you are not Stage IIB or IV." So the question to the thread is this. In Non-Small Cell Lung Cancer does stage II III recurrent disease carry a worse prognosis than IIIb/IV first onset? I think the answer is yes, much worse, even if lower stage, but I'm unsure. The question comes primarily from my experience with neuroblastoma, where staging, a historically important endeavour for prognosis, has been superseded by genetics. For example a high n-myc amplification confers a worse prognosis than a stage IV low n-myc amplification. So a recurrent stage I non small cell lung cancer might carry with it a worse prognosis than a more advanced stage if certain genetic factors caused it to be more capable of recurrence. Any help is welcome.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next